Follow-up studies have progressively revealed the extensive pro-carcinogenic effects of ZKSCAN3 in a variety of solid tumors (hepatocellular carcinoma, gastric cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer, epithelial ovarian cancer) and hematological tumors (multiple myeloma) (Figure 3) [5]. This evidence concerns the gene ZKSCAN3 and prostate cancer.